Zymeworks’ (ZYME) Neutral Rating Reiterated at HC Wainwright

Zymeworks (NYSE:ZYME)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price target would indicate a potential downside of 8.47% from the company’s current price.

Separately, Stifel Nicolaus lifted their target price on shares of Zymeworks from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, August 2nd.

Zymeworks Stock Down 0.2 %

Shares of NYSE:ZYME opened at $13.11 on Tuesday. The company has a market cap of $926.94 million, a P/E ratio of -7.32 and a beta of 1.20. The company’s fifty day moving average is $12.23 and its two-hundred day moving average is $10.26. Zymeworks has a 12-month low of $6.51 and a 12-month high of $14.05.

Zymeworks (NYSE:ZYME) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. The firm had revenue of $19.24 million during the quarter, compared to the consensus estimate of $23.16 million. During the same period in the prior year, the business earned ($0.76) EPS. Equities research analysts anticipate that Zymeworks will post -0.85 earnings per share for the current year.

Institutional Trading of Zymeworks

Several large investors have recently added to or reduced their stakes in the business. Rubric Capital Management LP raised its holdings in shares of Zymeworks by 12.7% during the 2nd quarter. Rubric Capital Management LP now owns 3,917,331 shares of the company’s stock valued at $33,336,000 after purchasing an additional 441,947 shares in the last quarter. Vanguard Group Inc. raised its holdings in Zymeworks by 2.6% during the first quarter. Vanguard Group Inc. now owns 2,458,105 shares of the company’s stock valued at $25,859,000 after buying an additional 63,393 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in shares of Zymeworks by 1.2% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,930,887 shares of the company’s stock worth $16,431,000 after buying an additional 23,173 shares during the last quarter. Perceptive Advisors LLC boosted its stake in shares of Zymeworks by 55.2% during the 2nd quarter. Perceptive Advisors LLC now owns 1,667,711 shares of the company’s stock worth $14,192,000 after acquiring an additional 592,904 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Zymeworks by 4.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,305,057 shares of the company’s stock valued at $13,724,000 after acquiring an additional 51,036 shares during the last quarter. 92.89% of the stock is owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.